This phase II trial was designed to determine the safety and efficacy of a modified paediatric risk‐stratified protocol in young adults (18–30years) with classical Hodgkin Lymphoma. The primary end‐point was neurotoxicity rate. The incidence of grade 3 neurotoxicity was 11% (80% CI, 5–19...
The treatment of classical Hodgkin lymphoma (cHL) in children is a story of success. Nowadays, more than 90% of patients are cured and overall survival is nearly 100% at 5years. Efforts have been made to avoid related effects of therapies; therefore, children are treated using different ...
大多数经典型霍奇金淋巴瘤(classic Hodgkin lymphoma, cHL)患者在初始治疗后会达到完全缓解,并实现长期疾病控制/治愈。然而,预后良好的早期cHL患者中有10%-15%复发,晚期cHL的复发率为15%-30%[1-7]。约10%-15%的患者的疾病难治,对初始治疗无反应或在初始治疗获得部分缓解后出现进展。
Hodgkin lymphoma, uncommon cancer of the lymphatic system (malignant lymphoma) that usually strikes young adults and people age 55 or older. Most patients can be cured if the disease is detected in its early stages. Learn about the causes, symptoms, and
Treatment protocols for classical Hodgkin lymphoma (HL) are provided below, including treatment for early-stage, advanced-stage, and relapsed/refractory disease. General guidelines follow. Check specific guidelines for restaging and dosage adjustments for chemotherapy and/or radiation therapy depending on ...
Classical Hodgkin's lymphoma (cHL) is an unusual lymphoid neoplasm, and nearly 50% of patients still relapse after standard therapy. Programmed cell death protein 1 (PD-1) signaling plays a vital in the progression of cHL. Anti-PD-1 antibodies such as nivolumab and pembrolizumab have thus bee...
depending on the type and stage of the illness. Understand the basics of lymphoma, the differences between Hodgkin and non-Hodgkin lymphoma, and why some people may be more susceptible to this type of cancer. Your doctor can help you find the right treatment for your type and stage of the...
depending on the type and stage of the illness. Understand the basics of lymphoma, the differences between Hodgkin and non-Hodgkin lymphoma, and why some people may be more susceptible to this type of cancer. Your doctor can help you find the right treatment for your type and stage of the...
Despite complete remission rates of up to 90%, late toxicities, such as secondary malignancies and cardiovascular events, are key concerns in patients treated for early-stage Hodgkin lymphoma. Catherine Diefenbach, MD The widely accepted standard of care for patients with early-stage Hodgkin lym...
Michael R. Bishop, MD, discusses chimeric antigen receptor T cells therapy in non-Hodgkin lymphoma.